Arcus Biosciences, Inc.
NYSE:RCUS · New York Stock Exchange
-$0.09 today
Vol 1.12M · Avg 1.17M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$353.0M -24.7% | -$283.0M +7.8% | -$307.0M -15.0% | -$267.0M -605.4% | $52.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $10.0M +0.0% | $10.0M +25.0% | $8.0M -42.9% | $14.0M +264.3% | $3.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $4.8M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $60.0M -21.1% | $76.0M +4.1% | $73.0M +12.3% | $65.0M +18.2% | $55.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$194.0M -981.8% | $22.0M +131.0% | -$71.0M -111.4% | $623.0M +265.9% | -$375.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $9.0M -67.9% | $28.0M +86.7% | $15.0M -97.9% | $704.0M +4230.0% | -$17.0M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $14.1M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $24.0M +700.0% | $3.0M +400.0% | -$1.0M -112.5% | $8.0M +267.6% | -$4.8M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$227.0M -2422.2% | -$9.0M +89.4% | -$85.0M +4.5% | -$89.0M +75.8% | -$367.9M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$5.0M -200.0% | $5.0M +155.6% | -$9.0M -113.2% | $68.0M +1857.4% | $3.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$482.0M -183.5% | -$170.0M +44.4% | -$306.0M -169.9% | $438.0M +271.0% | -$256.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$2.0M +66.7% | -$6.0M +75.0% | -$24.0M -300.0% | -$6.0M +77.0% | -$26.1M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 +100.0% | -$22.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$1.1B -3.2% | -$1.0B -32.4% | -$788.0M +36.5% | -$1.2B -72.6% | -$718.9M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $1.1B +18.5% | $965.0M -4.1% | $1.0B +20.2% | $837.0M +12.9% | $741.1M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 +100.0% | -$3.0M -113.6% | $22.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $66.0M +178.6% | -$84.0M -143.3% | $194.0M +147.0% | -$413.0M -10577.4% | -$3.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $49.0M +4.3% | $47.0M | $0 -100.0% | $10.0M +100.0% | $5.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $439.0M +92.5% | $228.0M +812.0% | $25.0M +8.7% | $23.0M -89.5% | $220.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 +100.0% | -$6.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $2.0M -75.0% | $8.0M | $0 -100.0% | $12.3M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $488.0M +76.2% | $277.0M +739.4% | $33.0M +0.0% | $33.0M -86.1% | $237.3M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 -100.0% | $86.0K | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $72.0M +213.0% | $23.0M +129.1% | -$79.0M -236.0% | $58.1M +355.9% | -$22.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$484.0M -175.0% | -$176.0M +46.7% | -$330.0M -176.4% | $432.0M +253.1% | -$282.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.40B
Liquidia Corporation
NASDAQ:LQDA
$6.03B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.87B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.71B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.39B
89bio, Inc.
ETNB
$2.20B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$2.11B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.01B
Galapagos N.V.
GLPG
$1.84B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.50B
SEC Filings
Recent regulatory filings
No filings found.
Does RCUS generate free cash flow?
Arcus Biosciences, Inc. (RCUS) generated -$484,000,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does RCUS produce?
Operating cash flow was -$482,000,000.00, before capital expenditures of $2.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.